JP MORGAN/CALL/BRISTOL-MYERS SQUIBB/60/0.1/17.01.25 | Market Closed - Börse Stuttgart 12:07:59 2024-07-12 pm EDT | ||
| 0.014 EUR | -22.22% |
|
| Current month | -22.22% | ||
| 1 month | -41.67% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 0.014 | -22.22% |
| 24-07-11 | 0.018 | 0.00% |
| 24-07-10 | 0.018 | +20.00% |
| 24-07-09 | 0.015 | +7.14% |
| 24-07-08 | 0.014 | -12.50% |
Delayed Quote Börse Stuttgart
Last update July 12, 2024 at 12:07 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | J.P. Morgan |
| WKN | JL970T |
| ISIN | DE000JL970T1 |
| Date issued | 2023-08-08 |
| Strike | 60 $ |
| Maturity | 2025-01-17 (189 Days) |
| Parity | 10 : 1 |
| Emission price | 0.7 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.86 € |
|---|---|
| Lowest since issue | 0.012 € |
| Spread | 0.015 € |
| Spread % | 51.72% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
40.46
USD
Average target price
52.74
USD
Spread / Average Target
+30.35%
- Stock Market
- Warrants
- Warrant
